MeSH D019694 - chronic hepatitis b
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Emtricitabine, Tenofovir disoproxil, Efavirenz | Efavirenz, Emtricitabine, Tenofovir Disoproxil |  | 2018-11-09 |  |  |
| Emtricitabine, Tenofovir disoproxil | Emtricitabine Tenofovir Disoproxil |  | 2017-06-08 |  |  | |
| Entecavir | Entecavir |  | 2014-08-26 |  |  | |
| Lamivudine | Lamivudine Teva |  | 2009-10-23 |  |  | |
| Tenofovir disoproxil | Tenofovir Disoproxil |  | 2015-03-18 |  |  | |
| Mylan | Tenofovir disoproxil, Lamivudine | Cimduo |  | 2018-02-28 |  |  |
| Emtricitabine, Tenofovir disoproxil, Efavirenz | Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan |  | 2017-09-05 |  |  | |
| Emtricitabine, Tenofovir disoproxil | Emtricitabine Tenofovir Disoproxil |  | 2018-04-09 |  |  | |
| Emtricitabine, Tenofovir disoproxil | Emtricitabine/Tenofovir disoproxil Mylan |  | 2016-12-16 |  |  | |
| Entecavir | Entecavir Mylan |  | 2017-09-18 |  |  | |
| Tenofovir disoproxil, Efavirenz, Lamivudine | Symfi |  | 2018-03-22 |  |  | |
| Tenofovir disoproxil, Efavirenz, Lamivudine | Symfi Lo |  | 2018-02-05 |  |  | |
| Tenofovir disoproxil | Tenofovir Disoproxil |  | 2018-11-27 |  |  | |
| Tenofovir disoproxil | Tenofovir disoproxil Mylan |  | 2016-12-08 |  |  | |
| Johnson & Johnson | Tenofovir alafenamide, Cobicistat, Emtricitabine, Darunavir | Symtuza | 2022-02-02 | 2018-07-17 |  |  |
| GSK | Lamivudine | Zeffix |  | 1999-07-29 |  |  |
| Roche | Ribavirin, Peginterferon alfa-2a | Pegasys Copegus |  | 2004-06-04 |  |  |
| Cipla | Emtricitabine, Tenofovir disoproxil, Efavirenz | Efavirenz, Emtricitabine, Tenofovir Disoproxil |  | 2019-06-03 |  |  |
| Emtricitabine, Tenofovir disoproxil | Emtricitabine Tenofovir Disoproxil |  | 2021-04-02 |  |  | |
| Entecavir | Entecavir |  | 2016-12-06 |  |  | |
| Tenofovir disoproxil | Tenofovir Disoproxil |  | 2018-01-26 |  |  | |
| Chartwell Pharmaceuticals | Emtricitabine, Tenofovir disoproxil | Emtricitabine Tenofovir Disoproxil |  | 2021-06-04 |  |  |
| Tenofovir disoproxil | Tenofovir Disoproxil |  | 2018-07-26 |  |  | |
| Tenofovir disoproxil, Lamivudine | Temixys |  | 2018-11-16 |  |  | |
| Entecavir | Entecavir |  | 2016-11-23 |  |  | |
| Novartis | Telbivudine | Sebivo |  | 2007-04-24 |  |  |
| Telbivudine | Tyzeka | 2023-09-11 | 2006-10-25 |  |  | |
| Merck Sharp & Dohme | Doravirine, Tenofovir disoproxil, Lamivudine | Delstrigo | 2031-10-07 | 2018-08-30 | $100 M | Q1/23-Q1/24 |
| Interferon alfa-2b | Intron A |  | 1986-06-04 |  |  | |
| Interferon alfa-2b | IntronA |  | 2000-03-09 |  |  | |
| Interferon alfa-2b | Viraferon |  | 2000-03-09 |  |  | |
| Aurobindo Pharma | Emtricitabine, Tenofovir disoproxil, Efavirenz | Efavirenz, Emtricitabine, Tenofovir Disoproxil |  | 2018-09-04 |  |  |
| Tenofovir disoproxil, Efavirenz, Lamivudine | Efavirenz, Lamivudine Tenofovir Disoproxil |  | 2018-08-15 |  |  | |
| Emtricitabine, Tenofovir disoproxil | Emtricitabine Tenofovir Disoproxil |  | 2018-01-26 |  |  | |
| Entecavir | Entecavir |  | 2015-08-26 |  |  | |
| Tenofovir disoproxil, Lamivudine | Lamivudine Tenofovir Disoproxil |  | 2018-05-15 |  |  | |
| Tenofovir disoproxil | Tenofovir Disoproxil |  | 2018-01-26 |  |  |
1
2
3
4
>
Clinical Trials
Historical Success Rate
Phase 1
55%21/38
Phase 2
65%30/46
Phase 3
70%28/40
Approved: 12Overall Success rate: 25%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use